Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease: A Review of Symptomatic and Potential Disease-Modifying Effects

Author： Schapira Anthony H.V.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.25, Iss.12, 2011-12, pp. : 1061-1071

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoamine Oxidase B Inhibitors in Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 4, 2017-07 ,pp. : 425-439

Bentham Science Publishers

Access to resources Recommend Favorite

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

By Elmer Lawrence W   Bertoni John M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2759-2772

Informa Healthcare

Access to resources Recommend Favorite

Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 6, 2015-01 ,pp. : 777-785

Bentham Science Publishers

Access to resources Recommend Favorite

Community and Long-Term Care Management of Parkinson's Disease in the Elderly: Focus on Monoamine Oxidase Type B Inhibitors

By Chen Jack J.  

Drugs & Aging, Vol. 24, Iss. 8, 2007-01 ,pp. : 663-680

Adis International

Access to resources Recommend Favorite

Donepezil: potential neuroprotective and disease-modifying effects

By Jacobson Sandra A   Sabbagh Marwan N  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 10, 2008-10 ,pp. : 1363-1369

Informa Healthcare

Access to resources Recommend Favorite